Undergoing a bilateral risk-reducing mastectomy (BRRM) appears to improve breast cancer-specific survival (BCSS) and overall survival (OS) in healthy women who are carriers of the BRCA1 mutation, according to a study from The Netherlands. Conversely, women carrying the BRCA2 mutation had similar BCSS regardless of whether they underwent BRRM or surveillance.
Neoadjuvant chemotherapy plus targeted anti-HER2 therapy may reduce the need for mastectomy and lymph node removal in women with HER2-positive breast cancer, according to a study from Spain that was presented at EBCC 2018.
A single administration of the fixed-dose combination consisting of netupitant plus palonosetron (NEPA) in addition to dexamethasone may be an effective strategy for preventing chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving combination chemotherapy consisting of anthracycline and cyclophosphamide (AC), according to results from the GIM15-NEPA* trial presented at EBCC 2018.
The addition of the selective CDK*4/6 inhibitor ribociclib to a regimen consisting of tamoxifen or a non-steroidal aromatase inhibitor (NSAI) and goserelin prolonged progression-free survival (PFS) and generated a higher objective tumour response rate in pre- or perimenopausal women with HR-positive, HER2-negative advanced breast cancer, according to additional results from the MONALEESA-7** trial presented at EBCC 2018.
Women with invasive breast cancer who received hypofractionated intensity modulated radiotherapy (IMRT) at a reduced dose or to only the tumour site (partial radiation) were less likely to report adverse events (AEs) than those who received standard dose IMRT to the whole breast, according to findings of the phase III, UK-based IMPORT LOW* trial.
Post-menopausal women diagnosed with oestrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery followed by whole breast radiotherapy have a reduced risk of developing local recurrence, according to a study from Italy.